Renal dysfunction and the treatment of inflammatory bowel disease (IBD): A case for monitoring

Australian and New Zealand Journal of Medicine

Volumn 28, Issue 3, 1998, Pages 346-

  Howard, G ^a   Lynn, K L ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; MESALAZINE; OLSALAZINE;

AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BARIUM ENEMA; CASE REPORT; CLINICAL FEATURE; COLON BIOPSY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; HUMAN; KIDNEY FAILURE; MALE; RECTUM HEMORRHAGE; ULCERATIVE COLITIS;

EID: 15644378538     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1998.tb01962.x     Document Type: Article

References (6)

1. Selby W. Current medical management of inflammatory bowel disease. J Gastroenterol Hepatol 1993; 8: 70-83.
2. Selby W. Clinical perspectives in inflammatory bowel disease. Aust NZ J Med 1996; 26: 15-29.
3. Riley SA, Lloyd DR, Mani V. Tests of renal function in patients with quiescent colitis: effects of drug treatment. Gut 1992; 33: 1348-52.
4. Word MJ, Stevens PE, Ashton MA, Rainford DJ. Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant 1996; 11: 614-21.
5. Staerk Laursen L, Stokholm M, Bukhave K, Rask-Madsen J, Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intra-luminal colonic concentrations, serum values and urinary excretion. Gut 1990; 31: 1271-6.
6. Behrens R, Ruder H. Chronic inflammatory intestinal disease and nephritis. Klin Padiatr 1992; 204: 61-4.